|
CEA-targeted engineered IL2: Clinical confirmation of tumor targeting and evidence of intra-tumoral immune activation. |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Celgene; Chugai Pharma; ImClone Systems; Lilly; Merck KGaA; Millennium; Novartis; Roche/Genentech; Sanofi; Symphony Evolution; Taiho Pharmaceutical |
|
|
Consulting or Advisory Role - Lilly; Novartis |
Research Funding - Roche Pharma AG (Inst) |
Travel, Accommodations, Expenses - Roche Pharma AG |
|
|
Honoraria - Bristol-Myers Squibb; Roche Pharma AG |
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Roche Pharma AG |
Research Funding - Pfizer (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche Pharma AG |
|
|
Research Funding - Roche Pharma AG (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme |
|
|
Speakers' Bureau - Bayer; Merck Serono |
Travel, Accommodations, Expenses - Amgen; Merck Serono; Roche Pharma AG; Sanofi |
|
|
Research Funding - Bristol-Myers Squibb (Inst); Janssen (Inst); Roche Pharma AG (Inst) |
Travel, Accommodations, Expenses - Janssen |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - ARIAD; Blueprint Medicines; Orion |
Consulting or Advisory Role - ARIAD; Blueprint Medicines; Orion |
|
|
No Relationships to Disclose |
|
Catharina Wilhelmina Menke |
Travel, Accommodations, Expenses - Amgen; Merck; Roche Pharma AG |
|
|
|
|
|
|
|
|
|
Stock and Other Ownership Interests - Proacta |
Patents, Royalties, Other Intellectual Property - Proacta |
|
|
|
Stock and Other Ownership Interests - Proacta |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Bristol-Myers Squibb; Roche Pharma AG |
|
|
No Relationships to Disclose |